Title:
自己由来抗原を特異結合細胞減少剤と同時に用いるB細胞病状の変更
Document Type and Number:
Japanese Patent JP5430824
Kind Code:
B2
Abstract:
A method of treating B cell malignancies or a method for preparing compositions for treating B cell malignancies wherein administration of a specific binding cytoreductive agent is followed by immunization with an autologous Id protein. The two treatments may be sequential, where the administration of the specific binding cytoreductive agent is completed before the administration of the autologous Id protein, or the administration of the specific binding cytoreductive agent and the immunization with an autologous Id protein may occur in an overlapping time course.
More Like This:
Inventors:
Daniel P. Gold
Application Number:
JP2006528206A
Publication Date:
March 05, 2014
Filing Date:
September 23, 2004
Export Citation:
Assignee:
MMRGlobal, INC.
International Classes:
A61K39/395; A61K38/00; A61K39/00; A61K39/385; A61K45/00; A61P35/00; C07K16/00; C07K16/28; C07K16/42; C12N1/19; C12N1/21; C12N15/00; C12N15/63; C12N
Other References:
WILSON, W.H et al,ANNALS OF ONCOLOGY,2002,Vol.13, No.Suppl.2,p.9
CZUCZMAN,M.S., CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma, Semin Oncol, 1999, Vol.26, No.5 Suppl 14, p.88-96
TIMMERMAN,J.M., Immunotherapy for lymphomas, Int J Hematol, 2003, Vol.77, No.5, p.444-55
MASSAIA,M. et al, Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy, Blood, 1999, Vol.94, No.2, p.673-83
RUFFINI,P.A. et al, Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines, Haematologica, 2002, Vol.87, No.9, p.989-1001
CZUCZMAN,M.S., CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma, Semin Oncol, 1999, Vol.26, No.5 Suppl 14, p.88-96
TIMMERMAN,J.M., Immunotherapy for lymphomas, Int J Hematol, 2003, Vol.77, No.5, p.444-55
MASSAIA,M. et al, Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy, Blood, 1999, Vol.94, No.2, p.673-83
RUFFINI,P.A. et al, Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines, Haematologica, 2002, Vol.87, No.9, p.989-1001
Attorney, Agent or Firm:
Kyousei Tamura
Samejima Mutsumi
Masahiro Nitta
Kure Hidenori
Samejima Mutsumi
Masahiro Nitta
Kure Hidenori